AGP Executive Report
Last update: 7 hours agoBiotech & Rare Disease: Neuren Pharmaceuticals surged 36% after Acadia’s DAYBU (trofinetide) won a positive CHMP recommendation in Europe for Rett syndrome neurobehavioral symptoms, moving to an expected European Commission decision in the coming months—potentially making it the first EU-approved option for this indication. Cancer Care: The EU also approved Merck/MSD’s KEYTRUDA plus Padcev perioperative and continued after surgery for cisplatin-ineligible resectable muscle-invasive bladder cancer, adding a new PD-1 inhibitor + antibody-drug conjugate pathway. More Oncology: Gilead’s Trodelvy gained EC marketing authorization as first-line monotherapy for unresectable or metastatic triple-negative breast cancer patients not eligible for PD-(L)1 inhibitors. Crypto Regulation (Liechtenstein): Bitcoin Suisse secured a MiCAR CASP license in Liechtenstein, giving it a regulated base to expand across selected EEA markets. Digital Payments & Stablecoins: OpenPayd obtained MiCA authorization to offer fiat-to-stablecoin on/off-ramping, custody and transfers across the EEA. Space Tech (Philippines): PhilSA and the Commission on Filipinos Overseas teamed up to boost youth participation and mobilize Filipino space experts abroad.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
